Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

erectile dysfunction

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

New dementia risk score ‘calculator’ shown to strongly identify disease risk

Targeting key risk factors could potentially avert around 40% of dementia cases

- PMLiVE

Study reveals gut conditions could be early sign of Parkinson’s disease

Constipation, dysphagia and IBS could be potential biomarkers of the condition

- PMLiVE

Study shows AI scans could detect Parkinson’s years before clinical presentation

OCT scans could be used by the NHS for the diagnosis of neurodegenerative diseases

- PMLiVE

Innovate UK awards Sano Genetics £330,000 grant for ALS study

The project will chart the psychological impacts of having a genetic predisposition to ALS

- PMLiVE

Alzheimer’s Research UK awards £370,000 to University of Exeter researchers

The grants are part of a wider £3m funding announcement that aims to accelerate effective treatments for dementia

- PMLiVE

Quest Diagnostics launches Alzheimer’s blood test for US consumers

Alzheimer's disease is expected to affect around 14 million people in the US by 2060

Biogen Idec building

Biogen/Eisai’s Alzheimer’s disease drug shows promise as a subcutaneous formulation

Leqembi was granted traditional approval in the US earlier this month as a bi-weekly intravenous infusion

- PMLiVE

Eli Lilly’s Alzheimer’s drug confirmed to significantly slow disease progression

The full phase 3 results presented at AAIC reinforce the cognitive benefits of donanemab

- PMLiVE

Alnylam presents promising results for RNAi therapeutic in Alzheimer’s disease at AAIC

ALN-APP is the first investigational RNAi therapeutic to show gene silencing in the human brain

- PMLiVE

Acumen shares positive results for investigational Alzheimer’s disease therapy at AAIC

The results will be discussed with regulators to assess next steps for clinical development

- PMLiVE

BMS obtains global rights to Prothena’s Alzheimer’s drug in deal worth $2.2bn

The decision comes two years after the company paid $80m for opt-in rights to PRX005

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links